Brenus Pharma, a pioneering French biotechnology start-up headquartered in Lyon, is excited to announce the successful completion of a €25 million funding round. This substantial investment will be instrumental in advancing the company's innovative platform technology, which focuses on delivering first-in-class tumor-antigen targeted immunotherapy. Brenus Pharma's unique approach employs Stimulated Tumor Cells (STC) technology to create an allogeneic product designed to effectively mimic the complex nature of tumors, addressing the significant challenges posed by tumor heterogeneity and treatment resistance.
The STC platform utilizes a three-step process beginning with the careful selection of cells that reflect tumor diversity, followed by in vitro induction to overexpress resistance markers and ensure the immune system recognizes the threats. By tagging these resistance markers through a haptenization process, Brenus Pharma's STC products are akin to therapeutic vaccines, priming patients' immune systems to combat cancer-related antigens that drive relapse mechanisms.
With the financial backing bolstered by seasoned experts such as co-founder J. Gardette, a well-respected healthcare entrepreneur, alongside B. Pinteur, a specialist in cellular therapies, and CEO P. Bravetti, Brenus Pharma is well-positioned to tackle the vast unmet needs in the realm of solid tumors. The funding will fuel further research and development, paving the way for groundbreaking solutions in immuno-oncology and enhancing treatment options for patients facing challenging cancers. Brenus Pharma's mission continues to be clear: to advance cutting-edge therapies that transform cancer care and ultimately improve patient outcomes.
.png&w=3840&q=75)
